No Data
No Data
Tracking of Hong Kong stock concepts | The Medical Insurance Bureau has announced the new medical insurance catalog. Institutions believe that the golden opportunity to increase the allocation of the pharmaceutical sector has already opened (including con
The National Medical Insurance Bureau has conducted preliminary reviews on 440 pharmaceuticals for this year's medical insurance catalog, which is an increase from last year.
Express News | Hansoh Pharmaceutical - Licensees Obtained Exclusive License From Lupeng Pharma to Develop and Commercialize LP-168 Within China
Express News | Hansoh Pharmaceutical - Hansoh (Shanghai) Healthtech, Others Entered License Agreement With Guangzhou Lupeng Pharmaceutical
Express News | Hansoh Pharmaceutical -Licensing Agreement With Lupeng Pharma
Hong Kong Stock Exchange News | Hansoh Pharma (03692) rose more than 3%, and the sales volume of Ametinib increased rapidly after its launch, with broad market growth potential in the future.
Hansoh Pharma (03692) rose more than 3% and at the time of publication, rose 3.25% to HKD 19.08 with a turnover of HKD 57.6911 million.
Some pharmaceutical stocks are rising against the market, and Beigene (06160) is up 5.03%. Institutions point to the pharmaceutical sector entering a value investment range.
Some pharmaceutical stocks bucked the trend, with BeiGene (06160) rising 5.03%, Shandong Xinhua Pharmaceutical (00719) rising 3.61%, Hansoh Pharma (03692) rising 2.38%, Joinn Laboratories (06127) rising 2.22%, and CanSinoBio (06185) rising 1.59%. News-wise, China International Capital Corporation released research reports stating that after 3 years of systematic adjustments, the pharmaceutical sector has entered the value investment range. Along with the gradual stabilization of domestic policies and the introduction of policies related to innovative drugs, the domestic innovative drug industry chain and overseas expansion are worth paying attention to in the second half of 2024.
No Data